4.2 Article

Is There Evidence for Vasculitis in Systemic Sclerosis?

Journal

CURRENT RHEUMATOLOGY REPORTS
Volume 14, Issue 6, Pages 516-525

Publisher

SPRINGER
DOI: 10.1007/s11926-012-0296-9

Keywords

Systemic sclerosis; Scleroderma; Vasculopathy; Vasculitis; Angiogenesis; Vasculogenesis; Endothelial cells; ANCA

Categories

Funding

  1. United Therapeutics Corp.
  2. InterMune
  3. Boehringer Ingelheim
  4. Actelion Pharmaceuticals Ltd.
  5. Celgene Corp.
  6. Sigma-Tau Pharmaceuticals
  7. Pfizer
  8. Ergonex Pharma
  9. Sanofi-Aventis

Ask authors/readers for more resources

Systemic sclerosis (SSc) is a devastating and potentially life-threatening multi-organ system disease. SSc is marked by skin thickening and tightening, Raynaud's phenomenon and digital ischemia with ulceration, gastrointestinal dysmotility, cardiopulmonary involvement with pulmonary fibrosis and pulmonary arterial hypertension, as well as renal failure. Fibrosis is the most obvious manifestation of SSc. Vascular involvement and inflammation are other prominent components of SSc pathology, and both features are also seen in vasculitis. This review analyzes whether there is evidence for vasculitis especially with particular organ manifestations and subgroups of patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available